Research Highlights: In a Phase 1, first-in-human trial, a one-time infusion of an investigational CRISPR-Cas9 therapy targeting angiopoietin-like protein 3 (ANGPTL3) was safe and reduced LDL cholesterol by nearly 50% and reduced triglycerides by...
  • Bababasti@feddit.orgEnglish
    14·
    8 days ago

    That is indeed a very heavy side effect and could potentially be a threat to human life on this planet.